🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "major milestone" in the fight against drug-resistant strains of the infection, according to scientists.

An International Challenge

Gonorrhoea infections are on the rise worldwide, with figures suggesting over 82 million instances each year. Especially elevated rates are reported in the African continent and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an important and timely development in the face of growing infection rates, increasing antimicrobial resistance and the very limited therapeutic options at this time.”

Health officials are increasingly worried about the surge in treatment-resistant strains. The global health body has designated it as a "critical concern". A tracking program showed that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Secure Authorization

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the US Food and Drug Administration in mid-December for use against gonorrhoea. This infection can lead to major issues, including infertility. Experts hope that focused deployment of this new drug will help slow the development of resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, gained clearance in close succession. This drug, which is employed against urinary tract infections, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

This new treatment stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to develop it.

“This authorization marks a major breakthrough in the therapy of highly resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Research Study Outcomes and Global Access

According to results released by a prominent scientific publication, zoliflodacin cured the vast majority of uncomplicated infections. This establishes an similar efficacy with the current standard treatment, which combines two antibiotics. The research enrolled nearly 1,000 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the rights to license and sell the drug in a wide range of regions with limited resources.

Doctors directly involved have voiced positive views. Access to a easy-to-administer therapy of this kind is seen as a "revolutionary step" for gonorrhoea control. This is deemed essential to reduce the burden of the illness for people and to prevent the spread of highly drug-resistant gonorrhoea globally.